hexarelin vs ipamorelin: Frequently asked questions

You've hit receptor desensitization—the expected outcome with all first-generation GHRPs. Options: (1) Switch to ipamorelin, which shows minimal desensitization over the same timeframe. (2) Implement a 3-days-on, 2-days-off hexarelin protocol to allow receptor resensitization, though this introduces pulsatile variability that may complicate continuous-outcome measurements. (3) Reduce hexarelin dose by 30–40% and accept lower but more stable GH output for the remainder of the study. For future protocols requiring consistent GH stimulus beyond 14 days, ipamorelin eliminates this problem entirely—one of the primary reasons it replaced earlier GHRPs in long-term research models.

Use ipamorelin in combination with a GHRH analogue like CJC-1295 (no DAC formulation). The GHRH + GHRP combination produces synergistic GH release—total output exceeds hexarelin alone by 20–30%—without engaging the stress axis. The mechanism: GHRH acts on pituitary somatotrophs from the hypothalamic side (cAMP pathway) while ipamorelin acts from the ghrelin receptor side (Gq protein-coupled pathway), producing a multiplicative effect rather than additive. This stack is standard in tissue repair and aging research where maximizing GH output without hormonal disruption is essential.

Switch to ipamorelin immediately and rebaseline your glucose measurements. Hexarelin's cortisol surge raises fasting glucose by 8–12% within 90 minutes of administration—this isn't a study design error, it's the peptide's mechanism. If your protocol measures insulin sensitivity, glucose tolerance, or any endpoint downstream of insulin receptor signaling, cortisol interference makes hexarelin-derived data uninterpretable. Ipamorelin produces the same GH-mediated insulin antagonism (a direct GH effect) without cortisol's additional impact, allowing you to isolate the variable you're actually testing.

Use Ipamorelin at higher doses (400–500 mcg per administration). While Hexarelin produces higher peak GH at lower doses, its tachyphylaxis after 4–6 weeks means the advantage disappears in protocols lasting longer than one month. Ipamorelin's resistance to desensitisation allows sustained GH elevation across 12–16 week research windows without washout interruptions. The cumulative GH exposure over time can match or exceed Hexarelin's short-term peaks.

You're experiencing receptor downregulation. This is expected. Discontinue Hexarelin and implement a 2–4 week washout period before restarting. Alternatively, switch to Ipamorelin for the remainder of the protocol. Its GHSR-1a selectivity means it doesn't accelerate the same desensitisation pathway Hexarelin triggers via CD36. If you must maintain GH elevation during the washout, Ipamorelin will continue working while Hexarelin receptors recover.

Use Ipamorelin exclusively. Hexarelin's cortisol spike (+25–40 ng/dL) is mechanistically unavoidable because CD36 activation in the hypothalamus stimulates corticotropin-releasing hormone (CRH) neurons upstream of ACTH secretion. Ipamorelin produces less than 5 ng/dL cortisol elevation. Functionally negligible and unlikely to confound metabolic, inflammatory, or body composition endpoints.

Hexarelin is the correct choice for protocols lasting 2–4 weeks where you need the highest possible GH pulse and can tolerate cortisol and prolactin elevation. Administer 150–200 mcg in a fasted state (minimum 3 hours post-meal, ideally upon waking) to maximise the pulse. Monitor cortisol and prolactin if those hormones intersect with your study endpoints. Hexarelin's CD36 activation will elevate both regardless of dose timing.

Choose ipamorelin without exception. Hexarelin's desensitization timeline means GH response amplitude drops 40–60% by week 16 even with dose escalation, whereas ipamorelin maintains consistent receptor sensitivity across six months of continuous daily use. Protocols requiring uninterrupted GH elevation cannot accommodate the 8–12 week washout hexarelin demands to restore pituitary responsiveness.

Hexarelin delivers 2–3× stronger peak GH pulses than ipamorelin at identical 100mcg doses, making it the superior choice for acute protocols lasting 8–12 weeks or less. The CD36 receptor co-activation amplifies downstream signaling beyond what ghrelin-selective compounds achieve, but this advantage disappears once desensitization begins.

Hexarelin's CD36 receptor activity triggers cardioprotective signaling (reduced infarct size, improved contractility) that ipamorelin lacks entirely. University of Pisa ischemia-reperfusion studies documented these effects independent of GH release, making hexarelin uniquely suited for dual-mechanism cardiovascular research. But only if the protocol fits within the 12–16 week pre-desensitization window.

Ipamorelin is the only GHRP that avoids HPA axis activation entirely. Hexarelin increases serum cortisol 20–35% at standard research doses, which matters in studies where glucocorticoid interference cannot be tolerated. The Journal of Clinical Endocrinology & Metabolism study comparing these compounds head-to-head confirmed ipamorelin's zero-cortisol profile across all tested doses.